Royalty Pharma Reports First Quarter 2025 Results
NEW YORK, NY, May 8th, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.
Investors
Keep up to date with all our latest financial information and events, and access our archives for historical data, presentations, statements and reports.
Latest results
Portfolio metrics
35+
Approved products
15
Development-stage therapies
15
Blockbuster products (>$1bn in annual sales)
~13year
Portfolio duration
Financial metrics
$2.8bn
Portfolio Receipts
(2024)
(2024)
$2.6bn
Adjusted EBITDA
(2024)
(2024)
$2.4bn
Average annual capital deployed (2019-2024)
$2.8bn
Announced value of transactions (2024)
Stock information
RPRX
${{TradePrice}}
{{TradeDate}}
Latest quarterly earnings
Q1 2025
Corporate presentation
Latest releases
Royalty Pharma Declares Second Quarter 2025 Dividend
NEW YORK, NY, April 21, 2025 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share.
Royalty Pharma To Announce First Quarter 2025 Financial Results On May 8, 2025
NEW YORK, NY, April 17, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open.
Royalty Pharma Appoints Vlad Coric, M.D. To The Company’s Board Of Directors
NEW YORK, NY, April 8, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately.
